EPIZYME INC's ticker is EPZM and the CUSIP is 29428V104. A total of 95 filers reported holding EPIZYME INC in Q2 2015. The put-call ratio across all filers is 0.71 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $1,852,000 | +22.6% | 153,062 | -0.3% | 0.00% | 0.0% |
| Q3 2016 | $1,510,000 | -4.2% | 153,494 | -0.2% | 0.00% | 0.0% |
| Q2 2016 | $1,576,000 | -7.9% | 153,876 | +8.9% | 0.00% | 0.0% |
| Q1 2016 | $1,712,000 | +10.9% | 141,251 | +46.5% | 0.00% | 0.0% |
| Q4 2015 | $1,544,000 | +24.6% | 96,396 | +0.1% | 0.00% | 0.0% |
| Q3 2015 | $1,239,000 | -47.2% | 96,314 | -1.5% | 0.00% | -33.3% |
| Q2 2015 | $2,346,000 | +192.5% | 97,769 | +128.9% | 0.00% | +200.0% |
| Q1 2015 | $802,000 | +21.3% | 42,721 | +22.0% | 0.00% | 0.0% |
| Q4 2014 | $661,000 | -31.1% | 35,022 | -1.0% | 0.00% | 0.0% |
| Q3 2014 | $959,000 | -44.2% | 35,375 | -35.9% | 0.00% | -50.0% |
| Q2 2014 | $1,719,000 | +303.5% | 55,226 | +195.3% | 0.00% | +100.0% |
| Q1 2014 | $426,000 | +24.9% | 18,700 | +13.9% | 0.00% | 0.0% |
| Q4 2013 | $341,000 | -49.1% | 16,417 | -2.0% | 0.00% | 0.0% |
| Q3 2013 | $670,000 | +58.0% | 16,747 | +11.1% | 0.00% | 0.0% |
| Q2 2013 | $424,000 | – | 15,078 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 31,833,334 | $47,750,000 | 19.42% |
| MPM BioImpact LLC | 3,425,202 | $3,939,000 | 1.06% |
| Palo Alto Investors LP | 6,774,541 | $7,791,000 | 0.60% |
| Foresite Capital Management I, LLC | 143,759 | $165,000 | 0.29% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 6,603,870 | $7,594,000 | 0.23% |
| Rock Springs Capital Management LP | 7,267,696 | $8,358,000 | 0.21% |
| BP PLC | 24,687 | $28,000 | 0.16% |
| NewGen Asset Management Ltd | 250,000 | $288,000 | 0.13% |
| GSA CAPITAL PARTNERS LLP | 467,836 | $538,000 | 0.07% |
| Frazier Life Sciences Management, L.P. | 739,369 | $850,000 | 0.07% |